Regeneron Pharmaceuticals faced a setback as its drugs fianlimab and Libtayo failed to meet endpoints in a phase 3 trial for first-line metastatic melanoma, causing shares to drop. However, this failure is not seen as critical for Regeneron's long-term value since fianlimab-based combinations were not central to its growth strategy. The company is still positioned for success due to its strong pipeline, balance sheet, and potential for growth. Key risks include possible further weakness in its Eylea franchise and other clinical trial disappointments.
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
Regeneron Pharmaceuticals' phase 3 trial for its melanoma drug fianlimab, combined with cemiplimab, failed to meet the primary goal of significantly improving progression-free survival compared to Merck's Keytruda. Although the combination extended m...
Regeneron Pharmaceuticals reported that its late-stage trial for the skin cancer drug fianlimab did not meet the primary endpoint, failing to outperform Merck's Keytruda. This setback caused Regeneron's stock to fall significantly in premarket tradin...
Regeneron Pharmaceuticals has entered a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates (AHCs), a novel therapy class aimed at difficult-to-treat targets. Regeneron will invest $125 million upfront and potenti...
Regeneron's Phase 3 trial testing fianlimab (LAG-3 inhibitor) combined with cemiplimab (PD-1 inhibitor) as first-line treatment for unresectable or metastatic melanoma did not achieve statistical significance for its primary endpoint of improved prog...
